镭-223在有或无同源重组基因缺陷的骨转移去势抵抗性前列腺癌中的疗效
该回顾性单中心研究纳入28例接受标准镭-223治疗的骨转移去势抵抗性前列腺癌(mCRPC)患者,其中10例(35.7%)携带胚系/体细胞同源重组缺陷(HRD)突变。HRD阳性患者碱性磷酸酶(ALP)缓解率更高(80% vs 39%,p=0.04),至ALP进展时间更长(中位10.4 vs 5.8个月,HR 6.4,p=0.005),总生存有延长趋势(中位36.9 vs 19.0个月,HR 3.3,p=0.11)。
要点
- HRD阳性mCRPC患者接受镭-223治疗后ALP缓解率显著高于HRD阴性者(80% vs 39%,p=0.04)。
- HRD阳性者至ALP进展时间显著延长(中位10.4 vs 5.8个月,HR 6.4,p=0.005)。
- 总生存有延长趋势但未达统计学显著(中位36.9 vs 19.0个月,HR 3.3,p=0.11)。
核心结论
- 在骨转移mCRPC中,携带HRD失活突变的患者接受镭-223治疗后ALP缓解和至ALP进展时间显著改善。
- 结果需前瞻性验证HRD突变与镭-223活性之间的「合成致死」假说。
研究设计与样本
- 回顾性单中心研究,复习190例有胚系和/或体细胞测序数据的mCRPC患者病历。
- 其中28例于2013年2月至2018年2月在约翰霍普金斯接受标准镭-223治疗。
主要发现
- 28例中10例(35.7%)携带胚系/体细胞HRD突变(BRCA2 3例,ATM、ATR、CHEK2、FANCG、FANCI、FANCL、PALB2各1例),18例(64.3%)无HRD突变。
- HRD阳性者较HRD阴性者ALP缓解率更高(80% vs 39%,p=0.04)。
- HRD阳性者至ALP进展时间更长(中位10.4 vs 5.8个月,HR 6.4,p=0.005)。
- HRD阳性者总生存有延长趋势(中位36.9 vs 19.0个月,HR 3.3,p=0.11)。
- 两组PSA缓解率(0% vs 0%,p>0.99)和至下一系统治疗时间(HR 1.5,p=0.39)相似。
关键数值与推荐
- HRD阳性者年龄数值上更低(66 vs 73岁,p=0.25),软组织转移更多(50% vs 38%,p=0.43),基线ALP更高(130 vs 108 U/l,p=0.84)。
临床怎么用
- 对于骨转移mCRPC患者,HRD突变状态可能有助于预测镭-223的ALP缓解和至ALP进展获益。
- 目前证据来自回顾性小样本探索性分析,尚不能据此常规改变临床决策。
局限性
- 回顾性分析性质。
- 样本量小(28例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pathogenic mutations in genes mediating homologous recombination (HR) DNA repair are present in 20-30% of men with metastatic castrate-resistant prostate cancer (mCRPC). Radium-223 is a bone-seeking α-emitter that induces double-strand DNA breaks, thereby killing cancer cells in the bone microenvironment. OBJECTIVE: To evaluate the potential impact of germline or somatic HR-deficiency (HRD) mutations on radium-223 efficacy in mCRPC with bone metastasis. DESIGN, SETTING, AND PARTICIPANTS: This is a retrospective single-institution study. Medical records of 190 mCRPC patients for whom germline and/or somatic DNA sequencing data were available were reviewed. Of these patients, 28 had received standard-of-care radium-223 at Johns Hopkins between February 2013 and February 2018. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Alkaline phosphatase (ALP) responses and time-to-ALP-progression were the coprimary endpoints. Prostate-specific antigen (PSA) responses, overall survival (OS), and time to next systemic therapy were also evaluated. RESULTS AND LIMITATIONS: Of the 28 patients included, 10 men (35.7%) had a germline/somatic HRD mutation (three in BRCA2, and one each in ATM, ATR, CHEK2, FANCG, FANCI, FANCL, and PALB2) and 18 (64.3%) did not. Men with HRD mutations (HRD+) had numerically lower ages (66 vs 73yr, p=0.25), more soft-tissue metastases (50% vs 38%, p=0.43), and higher baseline ALP levels (130 vs 108 U/l, p=0.84). Compared with HRD(-) men, HRD(+) patients showed greater ALP responses (80% vs 39%, p=0.04), longer time to ALP progression (median10.4 vs 5.8mo, hazard ratio [HR] 6.4, p=0.005), and a trend toward longer OS (median 36.9 vs 19.0mo, HR 3.3, p=0.11). PSA responses (0% vs 0%, p>0.99) and time to next systemic therapy (HR 1.5, p=0.39) were similar between the two groups. Results are limited by the retrospective nature of the analysis and the small sample size. CONCLUSIONS: In this exploratory study, bone-metastatic CRPC patients with inactivating HRD mutations demonstrated significantly improved ALP responses and time to ALP progression. These results should motivate prospective validation of the "synthetic lethality" hypothesis between HRD mutations and radium-223 activity. PATIENT SUMMARY: In this report, we retrospectively examined outcomes to metastatic prostate cancer in patients with and without DNA repair mutations who received radium-223, a therapy that kills cancer cells by causing direct DNA damage. Our study suggested that patients who have inherited or acquired DNA repair gene mutations derived greater benefit from radium-223 when compared with patients without these mutations. We concluded that radium-223 might have an important role in this setting; however, prospective studies are needed to confirm whether DNA repair mutations truly make radium-223 work better or not.
引用
- Isaacsson Velho P, Qazi F, Hassan S, et al. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects. Eur Urol. 2018. PMID: 30293905. doi:10.1016/j.eururo.2018.09.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。